Expo Hub
EUSOBI 2026
Innovating Personalized Breast Cancer Diagnostics.
For every woman. Everywhere.
Innovating Personalized Breast Cancer Diagnostics.
For every woman. Everywhere.
Thank you for joining us at EUSOBI 2025.
In the fight against breast cancer, we have achieved a lot. However, challenges remain: 1 in 8 breast cancers is still missed1, 50% of women receiving annual mammograms experience false-positive results2, and there is a significant shortage of radiologists and technologists to meet the growing demand for breast cancer screening and diagnosis.3 Our ambition is to change that — and to be your partner in delivering a more personalized approach to breast cancer diagnostics. Accurate imaging is essential for effective, individualized treatment.
At this year’s European Society of Breast Imaging, we showcased the latest innovations in breast imaging tailored to each patient’s needs:
- Fast, wide-angle DBT enabling 43% increased detection of invasive cancers4 and significant reduction of interval cancers when introduced in screening5
- CEM for significant increased detection of invasive cancers when introduced in BC surveillance6
- 40% faster and 2x higher resolution MRI with AI-powered reconstruction7
- Better lesion characterization with next-generation 2D SWE and its improved lesion deliniation8
- AI solution for signifcantly reduced reading time in tomosynthesis5 and 44% reduced reading workload in 2D (compared to double-reading)9
See you again next year!
Congress information
Date: October 1 – 3, 2026
Location: Maastricht, The Netherlands
Recordings of our sessions will be available soon
Related Products, Services & Resources
Thank you for joining us at EUSOBI 2025 in Aberdeen.
Products mentioned herein are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Next-gen CEM and next-gen CEM-powered Biopsy is under development and not commercially available. Ist future availability cannot be ensured.
1Ekpo EU, et al. (2018): Errors in Mammography Cannot be Solved Through Technology Alone.
2American Cancer Society (2022): Limitations of Mammograms. https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/mammograms/limitations-of-mammograms.html
3Advanced Health Education Center (2021): Radiology Staffing Shortages Nation Wide? https://aheconline.blog/2021/09/27/radiology-staffing-shortages-nation-wide/
4Compared to FFDM; Zackrisson S, Lång K, Rosso A, et al. (2018) One-view breast tomosynthesis versus two-view mammography in the Malmö Breast Tomosynthesis Screening Trial (MBTST): A prospective, population-based, diagnostic accuracy study
5Vilmun BM, Napolitano G, Lillholm M, et al. Introduction of one-view tomosynthesis in population-based mammography screening: Impact on detection rate, interval cancer rate and false-positive rate. Journal of Medical Screening. 2024;32(1):28-34. doi:10.1177/09691413241262259
6https://events.siemens-healthineers.com/sessions/symposium/rethinking-breast-cancer-follow-up
7Data on file
8Barr RG, Engel A, Kim S, et al. Improved Breast 2D SWE Algorithm to Eliminate False Negative Cases. Investigative Radiology. 2023
9van Winkel et al. Impact of artificial intelligence support on accuracy and reading time in breast tomosynthesis image interpretation. Eur Radiol. 2021;31:8682-8691; 6 https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00267-X/fulltext); Next-Gen AI is an option and available with Transpara® (FusionAI™ ScreenPointMedical)
MAMMOMAT B.brilliant is not commercially available in all countries. Its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
We reserve the right to make changes to the program.